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Rifampicin Alters Metformin Plasma Exposure 
but Not Blood Glucose Levels in Diabetic 
Tuberculosis Patients
Lindsey H.M. te Brake1,2,†, Vycke Yunivita3,†, Resvi Livia4, Nanny Soetedjo5,  
Eleonora van Ewijk-Beneken Kolmer1, Jan B. Koenderink2, David M. Burger1, Prayudi Santoso6,  
Reinout van Crevel7, Bachti Alisjahbana4, Rob E. Aarnoutse1, Rovina Ruslami3  
on behalf of the TANDEM Consortium
The pharmacokinetic (PK) and clinical implications of combining metformin with rifampicin are relevant to increasing 
numbers of patients with diabetic tuberculosis (TB) across the world and are yet unclear. We assessed the impact of 
rifampicin on metformin PKs and its glucose- lowering effect in patients with diabetic TB by measuring plasma metformin 
and blood glucose during and after TB treatment. Rifampicin increased metformin exposure: plasma area under the 
plasma concentration- time curve from time point 0 to the end of the dosing interval (AUC0–τ) and peak plasma 
concentration (Cmax) geometric mean ratio (GMR; during vs. after TB treatment) were 1.28 (90% confidence interval (CI) 
1.13–1.44) and 1.19 (90% CI 1.02–1.38; n = 22). The metformin glucose- lowering efficacy did not change 
(Δglucose − Cmax; P = 0.890; n = 18). Thus, we conclude that additional glucose monitoring in this population is not 
warranted. Finally, 57% of patients on metformin and rifampicin, and 38% of patients on metformin alone experienced 
gastrointestinal adverse effects. Considering this observation, we advise patients to take metformin and rifampicin with 
food and preferably separated in time. Clinicians could consider metoclopramide if gastrointestinal adverse effects occur.
Tuberculosis (TB) remains a leading cause of morbidity and mor-
tality in developing countries. In 2017, an estimated 10.0 million 
people developed active TB and 1.6 million patients died.1 At the 
same time, ~415 million people had diabetes mellitus (DM). The 
DM prevalence is growing rapidly, especially in low- income and 
middle- income countries, where TB is endemic. Furthermore, 
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Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE 
TOPIC?
 Metformin PKs is largely driven by drug transporter pro-
teins. Rifampicin is a known inducer of the expression of these 
transporters. In healthy volunteers, rifampicin previously led to 
higher exposure levels and enhanced glucose- lowering action.
WHAT QUESTION DID THIS STUDY ADDRESS?
 This study describes the impact of rifampicin on metformin 
PKs and its glucose- lowering effect in patients with diabetic TB.
WHAT DOES THIS STUDY ADD TO OUR 
KNOWLEDGE?
 This study was the first to evaluate the effect of rifampicin on 
metformin exposure and activity in patients with diabetic TB. 
The study provides the key leads for treatment optimization of 
this growing group of patients.
HOW MIGHT THIS CHANGE CLINICAL 
PHARMACOLOGY OR TRANSLATIONAL SCIENCE?
 We found that the PK interaction between rifampicin and 
metformin does not require additional glucose monitoring, in 
contrast to previous results in healthy volunteers. Because of a 
high incidence (> 50%) of gastrointestinal adverse events, we ad-
vise patients with diabetic TB to take metformin and rifampicin 
separated in time, and together with food and possibly metoclo-
pramide, to alleviate gastrointestinal adverse events as much as 
possible.
†These authors contributed equally to this work.
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DM increases the risk of developing active TB.2,3 Overall, there 
is an increasing number of TB cases attributable to DM, namely 
10% in 2010, and 15% in 2013.4
Patients with concurrent TB and DM face a higher risk of TB 
treatment failure, relapse after cure, and death.5 DM management 
in patients with TB is also problematic. The TB drug rifampicin 
may affect blood glucose concentrations and induce hyperglycemia 
by augmenting intestinal absorption of glucose or reducing insulin 
sensitivity.6,7 More importantly, rifampicin increases the clearance 
of most oral antidiabetic drugs that are commonly used in low- 
income to middle- income countries.8,9 For example, sulphony-
lureas are metabolized in the liver by cytochrome P450 enzymes, 
of which rifampicin is a very potent inducer.9,10
To overcome the effects of rifampicin on treatment and mainte-
nance of glycemic control, metformin has been proposed as a good 
alternative to other oral antidiabetic drugs, as it is not metabolized 
in the liver. Moreover, metformin is the first choice antidiabetic ac-
cording to type 2 DM treatment guidelines.11 The drug is relatively 
cheap, widely available, and not associated with weight gain or hy-
poglycemia.12,13 The main disadvantage of metformin is the risk 
for lactic acidosis and the high frequency of gastrointestinal adverse 
effects.14,15 The oral absorption, hepatic uptake, and renal excre-
tion of metformin are largely mediated by organic cation transport-
ers (OCTs) and multidrug and toxin extrusion protein 1 and 2K 
(MATE1 and MATE2K), all members of the solute carrier family 
(Figure 1).14 It is eliminated unchanged in the urine with a half- life 
of ~5 hours.14 Its renal clearance is greater than that of creatinine, 
indicating that tubular secretion contributes to its elimination.16
There is very limited data on co- administration of metformin 
and rifampicin and the need for dose adjustments in patients 
with TB- DM. Rifampicin is an agonist of the pregnane X recep-
tor (PXR), a transcription factor that upregulates a large number 
of genes involved in xenobiotic detoxification, including drug- 
metabolizing enzymes and drug transporters.17 In rats, the PXR 
agonist pregnenolone- 16- carbonitrile upregulated the expression 
of OCT1 in the liver and OCT2 in the kidneys, which signifi-
cantly reduced metformin plasma exposure.18 In healthy volun-
teers, rifampicin caused altered metformin absorption kinetics, 
leading to higher exposure levels and enhanced glucose- lowering 
action.19 Extrapolation of these results to complex patients with 
TB- DM should be made cautiously, because disease status can alter 
transporter expression levels,20–22 and patients with diabetes have 
altered glucose regulation compared with healthy volunteers.
In summary, the pharmacokinetic (PK) and clinical implications 
of combining metformin with rifampicin are relevant to increasing 
numbers of patients with TB with type 2 DM across the world and 
are yet unclear. We, therefore, assessed the effect of rifampicin on 
the steady- state PK parameters and glucose- lowering effect of met-
formin in patients with TB- DM.
RESULTS
Subjects
From the TANDEM TB- DM cohort, 57 patients were eligible 
and asked for informed consent, of which eventually 24 patients 
(12 women and 12 men) participated in the study. For further 
details on eligibility, inclusion, and exclusion of patients see 
Supplementary Files S1–S4. Nineteen patients were on 500 mg 
of metformin (test dose during PK day), of which two patients 
were once daily, nine patients were twice daily, four patients were 
thrice daily, and three patients were thrice daily in combination 
with 850 mg doses. One subject switched from twice daily 500 mg 
to thrice daily 500 mg in between the PK sessions. This was cor-
rected for by comparing area under the plasma concentration- time 
curve (AUC) across the entire dosing interval. Five patients were 
taking 850 mg of metformin (test dose during PK day) all thrice 
daily. Median fasting blood glucose during the first screen was 152 
(range: 91–329) mg/dL and estimated glomerular filtration rate 
(eGFR) amounted to 101 (range: 65–141) mL/min. Median age at 
both sessions was 51 years (range: 24–63 years). Body mass index 
remained comparable between sampling sessions 1 and 2, with 23 
(14–34) kg/m2 and 24 (16–35) kg/m2, respectively, supporting 
within- subject comparability of the two sessions (P = 0.339).
Effect of rifampicin on metformin PKs
Steady- state metformin PKs were assessed for subjects who un-
derwent PK sampling in the first (n = 24) and second session 
(n = 22; Table 1). Rifampicin increased metformin exposure: for 
rifampicin + metformin (during TB treatment) relative to met-
formin alone (after TB treatment) the geometric mean ratio 
(GMR) estimates of area under the plasma concentration- time 
curve from time point 0 to the end of the dosing interval (AUC0–τ) 
and peak plasma concentration (Cmax) were 1.28 (90% confidence 
interval (CI) 1.13–1.44) and 1.19 (90% CI 1.03–1.38), respec-
tively. Tubular secretion of metformin remained comparable 
(P = 0.777; Table 1 and Figure 2a–c). Creatinine clearance was 
slightly reduced (−4 mL/min) after rifampicin discontinuation 
Figure 1 Schematic overview of the most important transporters involved in the absorption, hepatic uptake, and excretion of 
metformin.14,38–42 The physiological significance of the transporters depicted in gray is unclear.14 MATE, multidrug and toxin extrusion; OCT, 
organic cation transporter; PMAT, plasma membrane monoamine transporter.
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Figure 2 Individual changes in steady- state metformin pharmacokinetic parameters, AUC0–τ (a), Cmax (b) and tubular secretion (c), with and 
without co- administration of rifampicin. Metformin plasma concentrations were extrapolated from 8 until 12–24 hours to calculate AUC0–τ for 
patients taking metformin once or twice daily. Tubular secretion was based on observed urine collections up to 8 hours after metformin intake. 
Data were assessed with paired- samples t test on the log- transformed parameters. AUC0–τ, area under the plasma concentration- time curve from 
time point 0 to the end of the dosing interval; Cmax, maximum plasma concentration. ETH, ethambutol; IC, informed consent; INH, isoniazid; MTF, 
metformin; PK- GC, pharmacokinetic- glucose curve sampling session; PZA, pyrazinamide; RIF, rifampicin.
Table 1 Comparison of steady- state metformin pharmacokinetic parameters and renal elimination parameters with and 
without co- administration of rifampicin
Parameter With rifampicin (n = 24) Without rifampicin (n = 22)
P value or 
GMR estimate (90% CI) 
(n = 22)
AUC0–τ (mg/L × hour) 15.4 (7.8–32.8) 12.1 (8.1–21.6) 1.28 (1.13–1.44)
a
Cmax (mg/L) 2.3 (1.25–5.22) 2.0 (1.10–3.86) 1.19 (1.03–1.38)
a
Tmax (hour) − median 1.5 (1–4) 1.5 (0–6)
CL/F (L/hour) 36 (21–69) 47 (34–73) <0.001b
Vd/F (L) 332 (201–681) 310 (87–477) 0.586
b
t1/2 (hour) 6.4 (4.2–17.2) 4.6 (1.6–6.6) 0.002
b
AUC0–8 hour (mg/L × hour) 13.4 (7.8–32.8) 10.9 (7.4–11.2) 0.001
AUC0–τ (mg/L × hour) –excluding sessions 
with ≥ 20% extrapolation
15.1 (7.8–32.8) 12.2 (8.1–21.6) 0.083 (n = 14)
CLcreatinine (mL/min)
c 110 (88–155) 106 (74–148) 0.005b
CL0–8 hour,renal (mL/min)
d 309 (90–625) 332 (126–659) 0.836b
CL0–8 hour,secretion (mL/min)
d 205 (–1–494) 219 (52–533) 0.777b
CL0–τ,secretion (mL/min)
d 212 (27–494) 216 (52–533) 0.856b
Metformin plasma concentrations were extrapolated from 8–12 or 24- hours postdose to calculate AUC0–τ for patients on once or twice daily metformin, 
respectively. Pharmacokinetic parameters are expressed as geometric mean (range), unless stated otherwise. AUC0–τ, area under the plasma concentration- time 
curve from time point 0 to the end of the dosing interval; CI, confidence interval; CL, clearance; Cmax, maximum plasma concentration; F, bioavailability; GMR, 
geometric mean ratio; t1/2, half- life; Tmax, time to maximum plasma concentration; Vd, volume of distribution.
aEvaluation of a pharmacokinetic interaction by means of the bioequivalence approach. bPaired- samples t test on log- transformed pharmacokinetic parameters. 
cSession comparison of creatinine clearance based on n = 21 individuals. dDue to miscollection of urine at home between 8 and 24 hours postdose for five 
individuals, we calculated renal clearance and tubular secretion from observed urine collections up to 8 hours after metformin intake (CL0–8 hour,renal (mL/min) and 
CL0–8 hour,secretion; n = 21), next to tubular secretion based on confirmed collections during the full time interval (CL0–τ,secretion) (n = 16).
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(P = 0.005; Table 1). The PK parameters of rifampicin are shown 
in Supplementary File S2 and demonstrate significant exposure 
to the perpetrator drug.
Effect of rifampicin on the glucose- lowering efficacy of 
metformin
Blood glucose concentrations for both sessions are displayed in 
Supplementary File S5. Fasting blood glucose concentrations 
differed slightly (15% reduction) during and after rifampicin treat-
ment, but this did not reach statistical significance (P = 0.081, 
n = 18; Table 2). Similarly, the ability of metformin to reduce 
maximum blood glucose levels (Gmax) and the AUC of glucose 
was not significantly different when measured during and after 
TB treatment (Table 2 and Figure 3).
Drug adherence and adverse events
Patients’ adherence to metformin and TB drugs was good. Mean 
percentages of drug adherence prior to the first session, according 
to physician assessment, pill count, self- assessment, and diary were 
100% (n = 24), 99% (n = 24), 100% (n = 24), and 92% (n = 19), 
respectively. Adherence was 100% (n = 22), 96% (n = 22), 100% 
(n = 22), and 100% (n = 17) for the second session, respectively. 
We expect any nonadherence to be of minor importance, because 
we actively stimulated drug intake during the final 3 days before 
PK sampling by personally contacting each patient.
Of the 24 patients who underwent PK sampling, 13 patients 
experienced gastrointestinal adverse event(s) when they took both 
metformin and rifampicin (57%; during TB treatment), and 8 
patients experienced gastrointestinal adverse event(s) when they 
took only metformin (38%; after TB treatment; Table 3). These 
additional gastrointestinal events could be attributed to more cases 
of nausea and vomiting (Table 3). Data do not include the cases 
that were excluded from the analysis due to vomiting on the PK- 
glucose curve (GC) days (Supplementary File S4). This occurred 
mainly prior to the addition of metoclopramide and separation of 
intake of metformin and TB drugs; four out of the first six patients 
vomited during PK- GC sampling session 1 (67%), with n = 2 
during PK- session 1 and n = 4 during GC- session 1. All adverse 
events were grades 1 or 2.
DISCUSSION
This study was the first to evaluate the effect of rifampicin on 
metformin exposure and activity in patients with TB- DM. We 
observed an increase in metformin exposure, with an AUC0–τ 
GMR (exposure during vs. after TB treatment) of 1.28 (90% CI 
1.13–1.44), suggesting a PK interaction (bio- inequivalence) when 
metformin is co- administered with rifampicin.23 This interaction 
did not result in a statistically significant change in the glucose- 
lowering effect of metformin.
Strikingly, renal clearance and tubular secretion were unaf-
fected by rifampicin in our study. Because metformin is also not 
metabolized, we hypothesize that the higher metformin total and 
peak exposures are the result of increased metformin absorption. 
Metformin has relatively poor oral absorption with a bioavailabil-
ity of 55%,14 leaving substantial space for absorption increases. 
OCT1, OCT3, and plasma membrane monoamine transporter 
(PMAT) are the relevant metformin transporters in the small 
intestine, with PMAT being the most abundant.14,24 Rifampicin- 
induced upregulation of these transporters is probably respon-
sible for the increased absorption assumed in our study. Indeed, 
Figure 3 Individual changes in G- AUC (a) and Gmax (b), after a 75- g glucose challenge, with and without co- administration of rifampicin. Data were 
assessed with paired- samples t test on log- transformed blood glucose parameters (n = 18). AUC, area under the blood concentration- time curve 
from; Gmax, maximum blood glucose concentration.
Table 2 The glucose- lowering effect of metformin with and without co- administration of rifampicin
Parameter
With rifampicin 
(n = 21) Without rifampicin (n = 18) P value
Baseline blood glucose (mg/dL) 127 (81–283) 148 (75–353) 0.081a
G- AUC0–3 hour (mg/dL × hour) 777 (523–1,488) 791 (509–1,459) 0.890
a
Gmax (mg/dL) 330 (223–597) 347 (214–595) 0.441
a
Data are expressed as geometric mean (minimum–maximum). G- AUC0–3 hour, area under the blood glucose concentration- time curve; Gmax, maximum blood 
glucose concentration.
aPaired- samples t test on log- transformed blood glucose parameters for n = 18.
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rifampicin increased OCT1 expression in blood cells in healthy 
volunteers.19 Further study is needed to evaluate the inductive 
effect of rifampicin on tissue (e.g., intestinal) expression of met-
formin transporters to confirm if this mechanism explains the 
rifampicin- metformin interaction.
The effect of rifampicin on systemic exposure to metformin is 
consistent with the findings of Cho et al.19 in healthy volunteers, 
although the PK interaction in our study seems larger (14–18% vs. 
17–30%). This difference may be explained by the enhanced renal 
clearance and tubular secretion in the healthy volunteer study, 
whereas we did not identify such an elimination effect. Disease 
status may have altered expression levels of transporters important 
for metformin elimination, such as OCT2, MATE1, or MATE2K. 
Information on the transcriptional regulation or inducibility of the 
MATE family in humans is lacking.
Importantly, increased metformin exposure in our study was 
not associated with any clinically relevant or statistically signifi-
cant increase in the glucose- lowering effect of metformin. Several 
explanations can be brought forward. First, rifampicin may have dif-
ferential effects on expression of the various drug transporters in the 
intestine, liver, and kidneys. In humans, the liver has a central role 
in the regulation of systemic glucose, but also the kidneys contrib-
ute to glucose uptake, gluconeogenesis, and glucose utilization.25,26 
Theoretically, altered OCT1 and OCT2 expressions influence local 
metformin exposure and, thus, overall drug efficacy. Unaffected ex-
pression would be in contrast with findings in rats, where the PXR 
agonist pregnenolone- 16- carbonitrile upregulated the expression of 
both OCT1 in the liver and OCT2 in the kidneys.18 Second, PXR 
itself is known to influence glucose homeostasis,27,28 and rifampicin 
has been reported to induce early phase hyperglycemia possibly by 
enhancing glucose absorption.6 These parallel processes may have 
counteracted or dampened a pharmacodynamic interaction.
To reduce the risk of gastrointestinal adverse effects, intake of met-
formin and rifampicin was separated in time and patients were pro-
vided with metoclopramide after a high incidence of vomiting in the 
initial patients (see Supplementary Files S4 and S6). Without these 
preventive measures we would not have been able to complete the 
study. Nonetheless, (mild) gastrointestinal adverse events remained 
extremely common, especially among patients with TB- DM on TB 
treatment and metformin (57%), with more nausea and vomiting 
compared with patients using metformin alone. Preventive actions 
should be considered when treating patients with TB- DM with 
metformin. Normally, it is advised to take TB drugs on an empty 
stomach, as food is known to limit their bioavailability,29 but they 
can also be taken with food if gastrointestinal adverse effects occur.
A limitation of this study is its sequential design; a clinically signif-
icant interaction might have led to adjustment of the metformin dose 
by the attending physician. Indeed, in three of the first seven subjects, 
the dosing interval of metformin had been changed after the first PK- 
GC session. Two of these patients could be measured in a third ses-
sion, after switching back to the dosing schedule of their first PK- GC 
session. Furthermore, bias as a consequence to the fixed sequence de-
sign could have been introduced by differences in comedication and 
food within- patient between sampling sessions. To avoid such inter-
ference, we standardized the timing and content of meals, as well as 
fixed the timing of intake of comedication (if any) to assure patients 
were sampled under comparable conditions throughout the study. 
Overall, we feel that our measures have been sufficient to prevent any 
confounding of the metformin- rifampicin drug- drug interaction and 
were, most importantly, mimicking the real- life clinical situation.
Another limitation is the use of creatinine clearance as estima-
tion for the fraction metformin eliminated from the body by glo-
merular filtration (eGFR). It is well known that creatinine is freely 
filtered by the glomerulus, however, active secretion by the proxi-
mal tubule also occurs.30 This possibly explains the slight change 
in creatinine clearance after stopping rifampicin (−4 mL/min; 
Table 3 Number of patients experiencing adverse events 
according to Common Terminology Criteria for Adverse 
Events version 4.032
System organ class
With rifampicin 
(n = 23)
Without rifampicin 
(n = 21)
All adverse events 
(grade 1 or 2)
17 (74%) 14 (64%)
Gastrointestinal 
disorders (grade 1 or 2)
13 (57%) 8 (38%)
Nausea 9 (39%) 5 (24%)
Grade 1 8 (35%) 5 (24%)
Grade 2 1 (4%) 0 (0%)
Vomiting 7 (30%) 4 (19%)
Grade 1 6 (26%) 4 (19%)
Grade 2 1 (4%) 0 (0%)
Diarrhea 3 (13%) 3 (14%)
Abdominal discomfort 0 (0%) 2 (10%)
Nervous system disorders
Headache 9 (39%) 6 (29%)
Grade 1 8 (35%) 6 (29%)
Grade 2 1 (4%) 0 (0%)
Musculoskeletal tissue disorders
Myalgia 8 (35%) 4 (19%)
Grade 1 8 (35%) 2 (10%)
Grade 2 0 (0%) 2 (10%)
Metabolism and nutrition disorders
Loss of appetite or 
anorexia
7 (30%) 3 (14%)
Respiratory disorders
Cough 5 (22%) 8 (38%)
General disorders
Flu 6 (26%) 3 (14%)
Fever 1 (4%) 1 (5%)
Edema 0 (0%) 1 (5%)
Skin and subcutaneous tissue disorders
Pruritus 2 (9%) 0 (0%)
Skin ulcer or ulcus 0 (0%) 2 (10%)
Rash 2 (9%) 1 (5%)
Number (%) of subjects with adverse events up to and including 
pharmacokinetic- glucose curve sampling session sampling session 1 (with 
rifampicin) and up to and including session 2 (without rifampicin). Grade 3 or 4 
adverse events were not observed.
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P = 0.005). The impact of this finding is minor; creatinine secre-
tion is only a small contributor to creatinine clearance, ~10–20% 
of the GFR,31 whereas renal clearance of metformin can be up to 
4–11 times as great as creatinine clearance.
As another limitation of our study, we cannot exclude an effect 
of isoniazid on the PKs and efficacy of metformin, as it was always 
co- administered with rifampicin in our study. However, to our 
knowledge, interactions of isoniazid with drug transporters have 
not been reported in literature. Similarly, we do not anticipate in-
teractions with metformin drug transporters caused by other con-
comitant drugs used by patients in this study.
Finally, we would like to note here that the average percentage 
of extrapolation for twice- daily dosing (from AUC0–8 hour until 
AUC0–τ was 21%; range: 15–26%), which is within acceptable 
limits for reliable extrapolation. Average percentage of extrapola-
tion for once- daily dosing was 29% (range: 14–36%), which may be 
considered bordering/exceeding reliable extrapolation. However, 
this only concerned two patients in the entire study. The compari-
son for nonextrapolated total exposures (AUC0–8 hour; i.e., with vs. 
without rifampicin), was similarly significant (P = 0.001; n = 22) 
as for AUC0–τ (Table 1, Figure 2). The comparison for AUC0–τ, 
excluding subjects with an AUC extrapolation > 20% for at least 
one sampling session, showed less significance (P = 0.083), prob-
ably because of a loss in power (n = 14), because geometric means 
and ranges were similar to AUC0–τ in the entire group (Table 1).
To summarize, we found that rifampicin exposure increases 
plasma metformin concentrations, without affecting its glucose 
lowering effect, suggesting that additional monitoring of glycemic 
control may not be necessary when treating patients with TB- DM. 
We observed a high incidence of gastrointestinal adverse effects, 
and, therefore, we advise patients to take metformin and rifam-
picin with food, and preferably separated in time. In addition, 
physicians could consider combining TB- DM treatment with 
metoclopramide as an anti- emetic when patients are experiencing 
gastrointestinal adverse effects.
METHODS
Subjects
Study subjects were Indonesian patients with pulmonary TB and type 2 
DM that had been included in the TANDEM study (ClinicalTrials.gov: 
NCT02106039) at the University of Padjadjaran, Bandung, Indonesia. 
Patients were enrolled if they were between 18 and 65 years of age; were 
taking metformin, irrespective of other blood glucose control drugs; were 
treated with the standard Indonesian continuation phase TB regimen 
containing rifampicin and isoniazid thrice weekly; had a stable renal 
function, classified as an eGFR of > 60 mL/min; and signed an informed 
consent. Patients were excluded if they had an alanine aminotransferase 
> 3 × upper limit of normal; had inadequately controlled blood glucose 
concentrations, classified as an average fasting blood glucose and 2- hour 
postprandial glucose ≥ 300 mg/dL; and were pregnant or lactating. The 
study was reviewed and approved by the Independent Ethics Committee, 
Faculty of Medicine, University of Padjadjaran, Bandung, Indonesia. All 
procedures were in accordance with the Helsinki Declaration of 1975 (as 
revised in 1983) and Good Clinical Practice.
After enrollment, patients underwent a physical screening just 
prior to the first sampling session, to test stable adequate liver (alanine 
aminotransferase < 3× upper normal limit) and kidney function (eGFR 
> 60 mL/min, calculated from plasma creatinine according to the Chronic 
Kidney Disease Epidemiology Collaboration formula32,33); to confirm 
adequately controlled blood glucose concentrations and to perform a 
pregnancy test, to ensure all inclusion criteria and exclusion criteria were 
still met, and patients were stable over time.
Study design
This was an open- label, one- arm (within- subject), two- period, fixed- order 
PK and pharmacodynamic interaction study. Figure 4 shows the schematic 
overview of the study design. Sampling occurred in two sessions to enable 
the assessment of metformin exposure when patients were on rifampicin 
and isoniazid during the last week of TB treatment, and after completion 
of TB treatment with a 1-month washout period in between.9 All patients 
were switched from thrice weekly to daily intake of TB drugs for at least 
> 7 days prior to the first PK sampling session, to match standard World 
Health Organization guidelines (dashed lines, Figure 4). The doses of 
rifampicin (450 or 675 mg) and isoniazid (300 mg) were once daily. The 
doses of metformin (500 or 850 mg) were once, twice, or thrice daily. In 
between the two sessions, an intermediate screening visit was planned to 
assess patient status once more.
The primary objective of this study was to evaluate the effect of 
rifampicin on the steady- state PKs of metformin. This was assessed with 
two 8- hour PK curves measured in plasma, together with urine collections 
during the dosing interval for estimation of renal clearance and tubular 
secretion. A PK sampling time period of 8  hours was selected, because 
the most frequent daily dosing was thrice daily metformin, which 
approximates a maximum of an 8- hour per dosing interval. Using the 
sample size nomograms by Diletti et al.,34 we estimated that 24 patients 
would be needed to conclude lack of an interaction (bioequivalence) 
with a power of 80% and a conservative estimate of the intra- individual 
coefficient of variation in metformin exposure of 25%. As a secondary 
objective, we evaluated the effect of rifampicin on the glucose- lowering 
effect of metformin by sampling two GCs following ingestion of 75  g 
of glucose on an empty stomach. Reported signs and symptoms were 
graded according to Common Terminology Criteria for Adverse Events 
4.0.35 Information on adverse events was collected throughout the study, 
starting from immediately after the screening visit, during all PK- GC days, 
and as part of the intermediate screening. The study was approved by the 
ethical review board of the Hasan Sadikin Hospital and Medical Faculty 
of Universitas Padjadjaran, Bandung, Indonesia.
Blood and urine collection during sampling sessions
Each of the two sampling sessions consisted of 2 days, one PK day and 
one GC day. During the PK days, metformin and rifampicin/isoniazid 
were initially taken together, and with food (n = 6), but this resulted in 
a high incidence of vomiting (n  =  4 in total; 2/6 patients during PK1 
Figure 4 Schematic overview of the study design in weeks from the 
start of tuberculosis (TB) treatment (wk 0). The TB treatment period 
(week 0–24) is colored dark gray. Patients were enrolled if they were 
continuation phase of TB treatment. Daily intake of TB drugs (for > 7 
days) is indicated by dashed lines. In between sessions, there 
was at least a 1-month washout period, after which any induction 
caused by rifampicin was expected to have dissipated.9 AUC, area 
under the plasma concentration- time curve; Cmax, maximum plasma 
concentration.
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and another 2/6 during GC1). Subsequently, patients were provided with 
oral metoclopramide (10 mg) 1 hour before taking metformin, and the 
TB drugs were ingested 3 hours after metformin. Patients were ordered 
to first take their breakfast and immediately afterward their metformin. 
Metoclopramide was the preferred anti- emetic, as there may be a drug- 
drug interaction between rifampicin and domperidone36 and there is 
less experience with the use of other anti- emetics in this setting. Eight 
serial blood samples were drawn at 0 (predose), 1, 2, 3, 4, 5, 6, and 8 hours 
after witnessed ingestion of metformin with a standardized breakfast. 
During the PK day, cumulative urine from all subjects was collected for 
8 hours in 2- hour intervals. Patients taking metformin once or twice daily 
received a urine container to collect their urine at home between the 8- 
hour until the 12–24- hour interval. Additional blood was withdrawn to 
assess plasma creatinine concentrations for the estimation of creatinine 
clearance.
On the second morning of each session, metoclopramide and metformin 
were taken once more, this time on an empty stomach. A total of 75 g of 
glucose was ingested on an empty stomach, at 2.5 hours after metformin 
intake when metformin concentrations are expected to be at their maximum 
(Cmax). Glucose concentrations were measured just before and at ½, 1, 1½, 
2, 2½, and 3 hours after ingestion of glucose. See Supplementary File S6 
for a schematic overview of the PK- GC sampling days.
Study drugs
All patients received 500 or 850  mg metformin tablets (Glucophage) 
from PT Merck ( Jakarta, Indonesia). TB drugs (rifampicin (450 mg) and 
isoniazid (300 mg)) were from PT Kimia Farma (Bandung, Indonesia), 
formulated in separate tablets. The bioequivalence of the rifampicin tablets 
and an international reference standard was established previously.37 
Metoclopramide (Metolon) 10  mg was provided by PT Bernofarm 
(Sidoarjo, Indonesia). Drug adherence was monitored from 1 week prior 
to the first PK session until the end of the study, using physician assessment, 
pill count, self- assessment, and a patient- kept diary.
Bio- analysis and PK evaluation
Plasma (metformin and rifampicin) and urine (metformin) 
concentration analyses were performed with validated ultraperformance 
liquid chromatography assays (Supplementary Files S1 and S2). 
Noncompartmental PK analyses were applied to calculate metformin 
and rifampicin PK parameters using Phoenix WinNonlin version 6.3 
(Pharsight, Mountain View, CA; Supplementary Files S2 and S3). The 
net tubular secretion of metformin was calculated by subtracting creatinine 
clearance from metformin renal clearance (total amount excreted divided 
by AUC0–τ; Supplementary File S3 for full details).
To assess changes in the glucose lowering effect of metformin, basal/
fasting blood glucose and Gmax were determined directly from the GC. 
The glucose AUC until 3 hours (G- AUC0–3 hour) was calculated using the 
Linear Trapezoidal Linear Interpolation rule using Phoenix WinNonlin.
Statistical analysis
Patient characteristics, metformin PKs, glucose data, and adverse 
events were presented descriptively for all patients included in the 
study. A bioequivalence approach was used to evaluate the metformin- 
rifampicin interaction. To conclude the absence of an interaction, or 
bioequivalence,34 the 90% CI of the GMRs of AUC- session 1:AUC- 
session 2 and Cmax- session 1: Cmax- session 2 should be between 0.80 and 
1.25. Further conclusions with regard to the presence of an interaction 
were drawn as described by Williams et al.23 To assess differences between 
sampling sessions in patient characteristics, metformin elimination, and 
glucose exposures, either Related- Samples Wilcoxon Signed Rank tests 
or paired- samples t tests on log- transformed plasma/blood parameters 
were performed. All statistical analyses were performed with IBM SPSS 
Statistics 22 for Windows. The P values < 0.05 were judged significant.
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